News

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
The Manila Times3h

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

BEACON-IPF close out activities continuePreviously announced workforce and operational realignment largely completePhase 1 ...

Cumberland (CPIX) Q2 Revenue Up 10%

Detailed price information for Cumberland Pharmaceu (CPIX-Q) from The Globe and Mail including charting and trades.

Broken Arrow mother fighting lung disease with the help of family, friends

Kristy Smith says in June she was diagnosed with idiopathic pulmonary fibrosis which caused scarring on the lungs and makes ...
Infectious Disease Advisor9h

2025 World Bronchiectasis Conference: New Care Models, Therapies on the Horizon

The 2025 World Bronchiectasis Conference highlighted new research on bronchiectasis and NTM - plus an emerging ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2025 Earnings Call Transcript

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...

Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 110+ Companies and Breakthrough Therapies Shaping the Future Landscape

In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with ...

MAX BioPharma and Revilico Announce Collaboration on Target Identification and Mechanistic Studies for Oxysterol Drug Candidates

MAX BioPharma and Revilico Collaboration LOS ANGELES, CA / ACCESS Newswire / August 6, 2025 / Today MAX BioPharma, Inc. ( and Revilico, Inc. ( announced their collaboration in studying the mechanisms ...